Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, ...

Major Finding: Glioblastoma cells recruit hybrid dendritic cell–like neutrophils to suppress tumor growth. Concept: Myeloid precursors from skull marrow differentiate within tumors to promote an ...

Healthcare services company Cardinal Health will acquire Integrated Oncology Network (ION) for about $1.12 billion. A physician-led operator of community cancer centers, ION includes more than 50 ...

Copyright held by the owner/author(s).

The development of second-generation covalent “off”-state KRAS G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with ...

University of Arkansas for Medical Sciences, Little Rock, AR, United States ...

Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth. Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD ...

Search for other works by this author on: ...

The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...